Making a tumor more sensitive to radiotherapy is a primary goal of combining chemo and radiation therapy to treat many types of cancer, but with the chemotherapy drugs come unwanted side effects. Now, investigators from the University of North Carolina report what they believe is the first pre-clinical demonstration of the potential of molecularly targeted nanoparticles as a promising new class of agents that can improve chemoradiotherapy treatment.
Scientists developed a method to combine a tumor-homing peptide, a cell-killing peptide, and a nanoparticle that both enhances tumor cell death and allows the researchers to image the tumors. When used to treat mice with glioblastoma, this new nanosystem eradicated most tumors in one model and significantly delayed tumor development in another.
Using magnetic nanoparticles as a sensitive readout of drug targeting, and a miniaturized nuclear magnetic resonance instrument, researchers created a novel system for directly measuring both target expression and drug binding in a small number of tumor cells obtained via needle biopsy.
Scientists have demonstrated that a superconducting detector called a transition edge sensor (TES) is capable of counting the number of as many as 1,000 photons in a single pulse of light with an accuracy limited mainly by the quantum noise of the laser source.
Is the emerging field of nanomedicine a breathtaking technological revolution that promises remarkable new ways of diagnosing and treating diseases? Or does it portend the release of dangerous nanoparticles, nanorobots or nanoelectronic devices that will wreak havoc in the body? A new review of more than 500 studies on the topic concludes that neither scenario is likely.
Some liquid crystals form monolayers on water surface. When compressed from sides, such films of monomolecular thickness can wrinkle like fabric on a flat, smooth table, pulled together with palms simultaneously from both sides. With increasing surface pressure, the wrinkles of the monolayer fold up and form subsequent layers.